© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
May 10, 2021
“In this study, we show that AI can be used to speed up the time-consuming step of outlining the prostate that's required for targeted prostate biopsy,” says Geoffrey Sonn, MD.
Ultra-high single-dose radiotherapy demonstrated comparable efficacy and safety as curative hypofractionated stereotactic body radiotherapy.
May 07, 2021
The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.
May 06, 2021
This article reviews new imaging technologies that may improve early detection of biochemical recurrence after definitive treatment for prostate cancer. This article also features insights from oncology experts Raoul Concepcion, MD; Judd Moul, MD; Brian Helfand, MD; Munir Ghesani, MD.
The final results of the pivotal TITAN trial “support the early addition of apalutamide to ADT for optimal therapeutic outcomes in patients with metastatic castration-sensitive prostate cancer,” the authors wrote.
May 03, 2021
Kretschmer highlights how ongoing research is aiming to optimize use of this noninvasive, urine-based genomic test.
April 29, 2021
"Three decades into prostate-specific antigen screening–detected prostate cancer, the prognostic and therapeutic impacts of various types of pelvic lymph node dissection remain unclear," writes Badar M. Mian, MD.
The ExoDx Prostate test helps physicians determine whether a prostate biopsy is necessary when PSA screening is ambiguous.
April 28, 2021
EPI-7386 previously received an FDA Fast Track Designation for patients with mCRPC resistant to standard-of-care treatments.
An expert panel reviews case studies in high-risk renal cell carcinoma and metastatic castration-resistant prostate cancer